{"id":38,"date":"2024-04-04T04:15:09","date_gmt":"2024-04-04T01:15:09","guid":{"rendered":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/23-kasutatud-allikad\/"},"modified":"2024-04-04T04:15:35","modified_gmt":"2024-04-04T01:15:35","slug":"23-kasutatud-allikad","status":"publish","type":"page","link":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/23-kasutatud-allikad\/","title":{"rendered":"2.3. Kasutatud allikad"},"content":{"rendered":"
    \n
  1. \n\t\tFaraji, A. H.; Wipf, P. (2009). Nanoparticles in cellular drug delivery, Bioorganic & Medicinal Chemistry, 17(8), pp. 2950\u20132962. doi: 10.1016\/j.bmc.2009.02.043.\n\t<\/li>\n
  2. \n\t\tFarmaatsiaterminoloogia andmebaas.https:\/\/ravimiamet.ee\/farmaatsiaterminoloogia-andmebaas<\/a> (05.09.19)\n\t<\/li>\n
  3. \n\t\tHilfiker. R. (2006). Polymorphism in Pharmaceutical Industry, Wiley-VCH; 1 edition.\n\t<\/li>\n
  4. \n\t\tHinrikus, T.; Kogermann, K.; Laius, O.; Leito, S.; Raal, A.; Soosaar, A.; Teppor, T.; Volmer, D. (2017). Farmaatsiaterminite l\u00fchendid, Eesti Arst 96(6):357\u2013363.\n\t<\/li>\n
  5. \n\t\tHinrikus, T.; Kogermann, K.; Laius, O.; Leito, S.; Raal, A.; Soosaar, A.; Teppor, T.; Volmer, D. (2019) Farmaatsiaterminoloogia 2 v\u00e4ljaanne.\n\t<\/li>\n
  6. \n\t\tKogermann, K. (2019). https:\/\/heureka.postimees.ee\/6760635\/karin-kogermann-iga-ravim-on-murk-koik-oleneb-annusest-ja-oigest-kasutamisest<\/a> (05.09.19)\n\t<\/li>\n
  7. \n\t\tKogermann, K. (2016). Originaalravimid ja geneerilised ravimid. T\u00e4ienduskonverents Kliinik 2016 (1.-3.02.2016). https:\/\/www.uttv.ee\/naita?id=23434&keel=eng<\/a> (05.09.19)\n\t<\/li>\n
  8. \n\t\tKogermann, K. (2018). Miks ja kuidas tehakse uusi ravimeid? Hambaarst, 60-66.\n\t<\/li>\n
  9. \n\t\tRavimiseadus, https:\/\/www.riigiteataja.ee\/akt\/104052016004<\/a>\n\t<\/li>\n
  10. \n\t\tPaaver, U.; Kogermann, K. (2015). Ravimvormide terminoloogia ja klassifitseerimine, Eesti Arst 94(4):242\u2013245.\n\t<\/li>\n
  11. \n\t\tPaaver, U.; Kogermann, K. (2016). Ravimvormide klassifikatsioon: tabletid (I), Eesti Arst 95(7):479\u2013484.\n\t<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Faraji, A. H.; Wipf, P. (2009). Nanoparticles in cellular drug delivery, Bioorganic & Medicinal Chemistry, 17(8), pp. 2950\u20132962. doi: 10.1016\/j.bmc.2009.02.043. Farmaatsiaterminoloogia andmebaas.https:\/\/ravimiamet.ee\/farmaatsiaterminoloogia-andmebaas (05.09.19) Hilfiker. R. (2006). Polymorphism in Pharmaceutical Industry, Wiley-VCH; 1 edition. Hinrikus, T.; Kogermann, K.; Laius, O.; Leito, …<\/p>\n","protected":false},"author":142,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-38","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/pages\/38","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/users\/142"}],"replies":[{"embeddable":true,"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/comments?post=38"}],"version-history":[{"count":1,"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/pages\/38\/revisions"}],"predecessor-version":[{"id":189,"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/pages\/38\/revisions\/189"}],"wp:attachment":[{"href":"https:\/\/sisu.ut.ee\/ravimitest-maakeeli\/wp-json\/wp\/v2\/media?parent=38"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}